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Status epilepticus (SE) is the second most common neurological
emergency, and frequently requires neurointensive care. SE
persisting despite treatment with benzodiazepines and antiepi-
leptic drugs is deﬁned as refractory status epilepticus (RSE).1 RSE
frequently occurs in people without structural brain damage and
carries a mortality rate of up to 40%.1While common causes of RSE
have been extensively studied, uncommon causes such as
autoimmune disorders and mitochondrial, genetic and metabolic
diseases like folic acid (FA) deﬁciency have been explored less and
are thus particularly challenging for the treating intensivist.2
Several therapeutic and diagnostic strategies have been suggested
for RSE, but none of these have been tested systematically.3
Advanced neuromonitoring techniques allow online measure-
ment of cerebral metabolic supply and demand.4 Depending on
molecular size and ionicity, several metabolites can be measured in
the extracellular ﬂuid of the human brain using cerebral
microdialysis. In patients with non-convulsive status epilepticus
(NCSE) following traumatic brain injury (TBI), an increase in lactate
to pyruvate ratio, as indicator of metabolic distress, has been* Corresponding author at: Division of Neurocritical Care, Department of
Neurology, Medical University Innsbruck, Anichstrasse 35 A-6020, Innsbruck,
Austria. Tel.: +43 512 504 81476.
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http://dx.doi.org/10.1016/j.seizure.2012.11.016described.5 In our report, the case of a patient with short bowel
syndrome and systemic FA deﬁciency who developed RSE is
described.
2. Case
A 47-year-old male was admitted to a primary care hospital
becauseofrecurrentcomplex partialseizures.Thepatienthad nopast
medicalhistory ofepilepsyortraumatic braininjury, buthadsuffered
severe abdominal trauma requiring partial colectomy (90 cm),
partial jejunectomy and terminal ileum resection 5 months before
admission. After surgery, he developed symptoms of short bowel
syndrome including chronic diarrhoea and weight loss. At that time,
folic acid and vitamin B12 levels were within normal ranges without
oral replacement therapy. His medication included colestyramine,
fenoﬁbrate and a selective serotonin re-uptake inhibitor.
At the primary care hospital, contrast enhanced computed
tomography (CT) of the brain was normal and electroencephalog-
raphy (EEG) revealed focal slowing over the right temporal region.
Anticonvulsive therapy with levetiracetam (2 g/day) was initiated.
However, the patient deteriorated and required intubation for
airway protection. He was transferred to our neurological intensive
care unit (NICU) and given antiepileptic treatment including
levetiracetam (3 g/day) and valproic acid (1.5 g/day). Laboratory
ﬁndings revealed normochromic, normocytic anaemia (haemo-
globin 10.2 g/dl; normal 13.0–17.7 g/dl; serum iron 3.5 mmol/l;
normal 11–28 mmol/l). The admission EEG (Fig. 1A) taken while
the patient was on midazolam (0.6 mg/kg/h), ketamine (0.6 mg/kg/
h) and sufentanil (1.7 mg/kg/h), demonstrated continuous rhyth-
mic epileptiform discharges over the right hemisphere. Intrave-
nous phenytoin was administered at a loading dose of 12 mg/kg/h
and continued with a maintenance dose of 9 mg/kg/day in order to
achieve a serum concentration of 20 mg/ml. After 24 h of combined
antiepileptic therapy and sedation, clinical ﬁndings and continu-
ous EEG readings were suggestive of persisting NCSE (Fig. 1A).
Treatment with thiopental was initiated at a loading dose of
425 mg (5 mg/kg) and titrated to induce a burst-suppression EEG
pattern (Fig. 1B), which persisted for 5 days.
Cerebral magnetic resonance imaging (MRI) demonstrated
cortical diffusion restriction of the entire right hemispherevier Ltd. All rights reserved.
Fig. 1. Eight channel EEGs. (A) Continuous rhythmic epileptiform discharges over the right hemisphere during midazolam/sufentanil/ketamine anaesthesia on admission, (B)
burst suppression pattern (duration of bursts: 1–2 s and duration of suppression: 6 s) during thiopental anaesthesia, (C) 9 days after admission, no deﬁnite ictal discharges,
diffuse theta slowing and blink artefacts.
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(Fig. 2A), but no abnormal contrast enhancement or structural
brain lesion. Cerebrospinal ﬂuid (CSF) analysis was unremarkable
and polymerase chain reaction for herpes simplex virus, varicella
zoster virus and cytomegalovirus was negative, as was serology for
neurotropic arthropod-borne viruses. Serum and CSF testing for
antithyroid antibodies, onconeuronal antibodies (Hu, Yo, Ma2,
CV2/CRMP-5, Amphiphysin and Ri) and antibodies against gluta-
mate receptors and voltage gated potassium channels were
negative.
Two days after admission, a microdialysis catheter was
implanted into the right frontal white matter (Fig. 2C) in order
to monitor brain metabolism. Cerebral microdialysis was approved
by the local ethics committee, details of which are given in
supplementary methods.
During the entire monitoring period, cerebral lactate levels
were normal (<4.0 mmol/l4) and lactate to pyruvate ratio was
below 40. Initially elevated glutamate levels (74.65 mmol/l;
normal 16  16 mmol/l4) signiﬁcantly decreased over time.
Before intravenous FA replacement therapy on the second day
after admission, serum FA levels were 3.4 mg/l (normal 4.6–18.7 mg/
l) and retrospectively evaluated brain FA levels were 2.2 mg/l.
Assuming an FA recovery rate of 21% (see supplementary methods),
post-hoc estimation of brain FA level was 10.4 mg/l. On the sixth day
after admission, FA levels increased to 11.6 mg/l (+241%) in serum
and to 3.9 mg/l (+77%) in the microdialysate of the brain.
Nine days after admission, EEG demonstrated diffuse theta
slowing without ictal discharges (Fig. 1C). Within the next 24 h, the
patient was extubated. There were no electrographic or clinical
seizures and imaging ﬁndings improved (Fig. 2C and D).
The patient was discharged to a neurological rehabilitation unit
21 days after admission. His discharge treatment consisted of
valproic acid (3 g/day), phenytoin (500 mg/day), lacosamid
(400 mg/day), levetiracetam (3 g/day) and oral FA replacement
therapy (5 mg/day). He remained seizure-free during the following
12 months and recovered to an independent state, returning to his
previous work. His current medication includes levetiracetam
(1.5 g/day), lacosamid (400 mg/day) and oral folic acid replace-
ment therapy (5 mg/day).
3. Discussion
To our knowledge, this case of a patient with FA deﬁciency and
RSE is the ﬁrst in vivo investigation of human brain FA levels during
seizure activity and after intravenous replacement therapy.Our patient suffered from short bowel syndrome following
partial colectomy and small intestine resection. Typical clinical
signs and symptoms of short bowel syndrome include chronic
diarrhoea resulting in intestinal malabsorption. This may well
explain FA deﬁciency in our patient.
FA transport into the central nervous system is adenosine
triphosphate-dependent and mainly occurs via speciﬁc transpor-
ters at the choroid plexus.6 There is a correlation between FA levels
in serum and in CSF.6 However, no data has been published on
cerebral extracellular FA levels in humans. Our report describes a
clear response of cerebral FA levels to intravenous replacement
therapy. We observed a FA brain to serum ratio of 3, with FA levels
increasing more in serum than in brain after intravenous
replacement therapy. These ﬁndings are consistent with a previous
study on rodents.7
RSE due to an inborn error of FA metabolism has been
previously reported in paediatric patients.8 FA as methyl donor
plays an important role in cerebral mitochondrial function and
nucleic acid synthesis.9 Moreover, a decrease of brain oxygenation
has been linked to FA deﬁciency,10 which may inﬂuence seizure
activity.
A recent report of a patient with status epilepticus and hypoxic
brain injury demonstrated that multimodal neuromonitoring,
including cerebral microdialysis, may be a feasible method for
evaluating secondary brain injury related to seizure activity.11 As
several processes deleterious to the human brain may occur in the
course of RSE, monitoring cerebral metabolism may be helpful for
interpretation of clinical and electrographic data.11 A lactate to
pyruvate ratio above 40 indicates a mismatch between cerebral
energy supply and demand, and has been described in patients
with status epilepticus after TBI5 and cardiac arrest.11We observed
a lactate to pyruvate ratio below 40, which could be explained by
the fact that we started cerebral microdialysis after initiation of
barbiturate anaesthesia. Furthermore, the microdialysis catheter
was placed in the cortico-medullar region 5 mm adjacent to
diffusion restrictions without structural lesions or brain oedema
on MRI.
Seizures due to metabolic disorders are commonly associated
with generalized epileptic activity, but may also be associated with
unilateral EEG-ﬁndings.12,13
The intensity of therapy in RSE is guided by continuous EEG-
readings. The target of the therapy is either the cessation of
electrographic seizures or the achievement of a burst suppression
pattern on surface EEG.14 Alongside other anaesthetics, we used
intravenous ketamine in our patient. Ketamine may have several
Fig. 2. (A) Diffusion weighted magnetic resonance imaging (DW-MRI) demonstrating hyperintense abnormalities of the right cortex, thalamus and caudate nucleus (24 h after
admission). (B) Axial computed tomography scan indicating the tip of the microdialysis catheter (arrow). MRI 20 days after admission showing (C) partial resolution of
diffusion restriction and (D) no structural brain lesions (proton density sequence).
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superior haemodynamic properties compared to propofol. Second,
ketamine as a non-competitive NMDA-receptor antagonist might
play a role in effective treatment of prolonged electrographic
seizures. We observed a decrease in levels of cerebral glutamate
over time. However, a causative relationship between cerebral
glutamate metabolism and ketamine treatment cannot be
concluded from this single observation.
Diffusion-weighted (DW)-MRI demonstrated hyperintense
signal abnormalities of the right cortex, caudate nucleus and
thalamus with partial resolution at follow-up imaging. DW-MRI
signal abnormalities following SE may involve the hippocampus,
cortical and thalamic structures and can persist for months.16
Important differential diagnoses of SE with MRI abnormalities
include Wernicke’s encephalopathy or limbic encephalitis. Herpes
simplex encephalitis was excluded by PCR and thiamine levelswere normal. Limbic encephalitis also has additional clinical
features such as subacute amnestic syndrome or psychiatric
symptoms. Moreover, the combination of absent onconeuronal,
NMDA and VGKC antibodies combined with unremarkable CSF-
ﬁndings makes the diagnosis of limbic encephalitis unlikely.
In conclusion, cerebral microdialysis is a feasible method for
monitoring brain metabolism during RSE. Furthermore, we
demonstrated that folic acid can be measured in cerebral
microdialysate and that brain folic acid levels were comparable
to results of previous animal studies. Although causality cannot be
proven, FA deﬁciency may have inﬂuenced the course of RSE in our
patient.
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Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.seizure.2012.11.016.
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